Bone and Calcium Metabolism

The Immunoassay Handbook

Volumn , Issue , 2013, Pages 705-720

  Fraser, William D ^a   Colston, Kay W ^b   Stevenson, John C ^b  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84883976709     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-08-097037-0.00058-0     Document Type: Chapter

References (50)

1. Aronov P.A., Hall L.M., Dettmer K., Stephensen C.B., Hammock B.D. Metabolic profiling of major vitamin D metabolites using Diels-Alder derivatization and ultra-performance liquid chromatography-tandem mass spectrometry. Anal. Bioanal. Chem. 2008, 391:1917-1930.
2. 3 in calcium stone formers with idiopathic hypercalciuria. Contrib. Nephrol. 1987, 58:137-142.
3. Binkley N., Krueger D.C., Morgan S., Wiebe D. Current status of clinical 25-hydroxyvitamin D measurement: an assessment of between-laboratory agreement. Clin. Chim. Acta 2010, 411:1976-1982.
4. 3 by isotope dilution-mass fragmentography. Clin. Chem. 1979, 25:584-588.
5. Body J.J., Heath H. Estimates of circulating monomeric calcitonin: physiological studies in normal and thyroidectomized man. J. Clin. Endocrinol. Metab. 1983, 57:897-903.
6. 3 in serum by liquid chromatography tandem mass spectrometry without derivatization. Eur. J. Mass Spectrom. (Chichester, Eng) 2010, 16:81-89.
7. Clemens J.D., Herrick M.V., Singer F.R., Eyre D.R. Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption. Clin. Chem. 1997, 43:2058-2063.
8. Clemens T.L., Hendy G.N., Graham R.F., Baggiolini E.G., Uskokovic M.R., O'Riordan J.L. A radioimmunoassay for 1,25-dihydroxycholecalciferol. Clin. Sci. Mol. Med. 1978, 54:329-332.
9. Clive D.R., Sudhaker D., Giacherio D., Gupta M., Schreiber M.J., Sackrison J.L., MacFarlane G.D. Analytical and clinical validation of a radioimmunoassay for the measurement of 1,25 dihydroxy vitamin D. Clin. Biochem. 2002, 35:517-521.
10. D'Amour P., Brossard J.-H., Rakel A., Rousseau L., Albert C., Cantor T. Evidence that the amino-terminal composition of non-(1-84) parathyroid hormone fragments starts before position 19. Clin. Chem. 2005, 51:169-176.
11. Delmas P.D., Garnero P. Biochemical markers of bone turnover in osteoporosis. Osteoporosis 1998, 117-136. Chapman and Hall Medical, London. J.C. Stevenson, R. Lindsay (Eds.).
12. Eastell R., Krege J.H., Chen P., Glass E.V., Reginster J.Y. Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr. Med. Res. Opin. 2006, 22:61-66.
13. Eisman J.A., Hamstra A.J., Cream B.E., DeLuca H.F. A sensitive, precise and convenient method for determination of 1,25-dihydroxyvitamin D in human plasma. Arch Biochem. Biophys. 1976, 178:235-243.
14. 3 in human plasma using high-pressure liquid chromatography. Anal. Biochem. 1977, 80:298-305.
15. Eriksen E.F., Charles P., Melsen F., Mosekilde L., Risteli L., Risteli J. Serum markers of type I collagen formation and degradation in metabolic bone disease; correlation with bone histomorphology. J. Bone Miner. Res. 1993, 8:127-132.
16. Eriksen F., Brixen K., Charles P. New markers of bone metabolism: clinical use in metabolic bone disease. Eur. J. Endocrinol. 1995, 132:251-263.
17. Ersfeld D.L., Rao D.S., Body J.J., Sackrison J.L., Miller A.B., Parikh N., Eskridge T.L., Polinske A., Olson G.T., MacFarlane G.D. Analytical and clinical validation of the 25 OH vitamin D assay for the LIAISON automated analyzer. Clin. Biochem. 2004, 37:867-874.
18. Fraser W.D., Robinson J., Lawton R., Durham B., Gallacher S.J., Boyle I.T., Beastall G.H., Logue F.C. Clinical and laboratory studies of new immunoradiometric assay of parathyroid hormone related protein. Clin. Chem. 1993, 39:414-419.
19. Fraser W.D., Durham B.H., Berry J.L., Mawer E.B. Measurement of plasma 1,25 dihydroxyvitamin D using a novel immunoextraction technique and immunoassay with iodine labelled vitamin D tracer. Ann. Clin. Biochem. 1997, 34:632-637.
20. Fraser W.D., Ahmad A.M., Vora J.P. The physiology of the circadian rhythm of parathyroid hormone and its potential as a treatment for osteoporosis. Curr. Opin. Nephrol. Hypertens. 2004, 13:437-444.
21. Fraser W.D. Hyperparathyroidism. Lancet 2009, 374(9684):145-158.
22. Gao P., Scheibel S., D'Amour P., John M.R., Rao S.D., Schmidt-Gayk H., Cantor T.L. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function. J. Bone Miner. Res. 2001, 16:605-614.
23. Garnero P., Vergnaud P., Hoyle N. Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis. Clin. Chem. 2008, 54:188-196.
24. 2 compared with HPLC: need for assay-specific decision limits and metabolite-specific assays. Ann. Clin. Biochem. 2006, 43:23-30.
25. Glendenning P., Chew G.T., Seymour H.M., Gillett M.J., Goldswain P.R., Inderjeeth C.A., Vasikaran S.D., Taranto M., Musk A.A., Fraser W.D. Serum 25-hydroxyvitamin D levels in vitamin D-insufficient hip fracture patients after supplementation with ergocalciferol and cholecalciferol. Bone 2009, 45:870-875.
26. Glover S.J., Eastell R., McCloskey E.V., Rogers A., Garnero P., Lowery J., Belleli R., Wright T.M., John M.R. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone 2009, 45:1053-1058.
27. Haddad J.G., Chyu K.J. Competitive protein binding radioassay for 25-hydroxycholecalciferol. J. Clin. Endocrinol. Metab. 1971, 33:992-995.
28. Halleen J.M., Alatalo S.L., Janckila A.J., Woitge H.W., Seibel M.J., Väänänen H.K. Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Clin. Chem. 2001, 47:597-600.
29. Hanson D.A., Weis M.A., Bollen A.M., Maslan S.L., Singer F.R., Eyre D.R. A specific immunoassay for monitoring human bone resorption; quantitation of type 1 collagen cross-linked N-telopeptides in urine. J. Bone Miner. Res. 1992, 7:1251-1258.
30. Hillyard C.J., Cooke T.J.C., Coombes R.C., Evans I.M.A., MacInytre I. Normal plasma calcitonin: circadian variation and response to stimuli. Clin. Endocrinol. 1977, 6:291-298.
31. 125I-labelled tracer. Clin. Chem. 1993, 42:586-592.
32. 125I-labelled tracer. Clin. Chem. 1996, 42:586-592.
33. Hollis B.W. Detection of vitamin D and its major metabolites. Vitamin D 1997, 587-606. Academic Press, Diego. D. Feldman (Ed.).
34. Hypponen E., Turner S., Cumberland P., Power C., Gibb I. Serum 25-hydroxyvitamin D measurement in a large population survey with statistical harmonization of assay variation to an international standard. J. Clin. Endocrinol. Metab. 2007, 92:4615-4622.
35. Dietary Reference Intakes for Calcium and Vitamin D 2011, IOM (Institute of Medicine), The National Academies Press., Washington, DC.
36. Manning E.M.C.M., Fraser W.D. A survey of diagnoses in patients with a low intact parathyroid hormone concentration. Ann. Clin. Biochem. 1993, 30:252-255.
37. 3. Clin. Chem. 2005, 51:1683-1690.
38. Melkko J., Kauppila S., Niemi S., Risteli L., Haukipuro K., Jukkola A., Risteli J. Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin. Chem. 1996, 42:947-954.
39. 3. Clin. Chem. 2011, 57:431-440.
40. Nussbaum S.R., Zahradnik R.J., Lavigne J.R., Brennan G.L., Nozawa-Ung K., Kim L.Y., Keutmann H.T., Wang C.A., Potts J.T., Segre G.V. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin. Chem. 1987, 33:1364-1367.
41. Ohashi T., Igarashi Y., Mochizuki Y., Miura T., Inaba N., Katayama K., Tomonaga T., Nomura F. Development of a novel fragments absorbed immunocapture enzyme assay system for tartrate-resistant acid phosphatase 5b. Clin. Chim. Acta 2007, 376:205-212.
42. Orum O., Hansen M., Jensen C.H., Sørensen H.A., Jensen L.B., Hørslev-Petersen K., Teisner B. Procollagen type 1 N-terminal propeptide (P1NP) as an indicator of type 1 collagen metabolism: ELISA development, reference interval and hypovitaminosis D induced hyperparathyroidism. Bone 1996, 19:157-163.
43. Pandian M.R., Morgan C.H., Carlton E., Segre G.V. Modified immunoradiometric assay of parathyroid hormone-related protein: chemical application in the differential diagnosis of hypercalcemia. Clin. Chem. 1992, 38:282-288.
44. Price C.P., Thompson P.W. The role of biochemical tests in the screening and monitoring of osteoporosis. Ann. Clin. Biochem. 1995, 32:244-260.
45. Ratcliffe W.A., Norbury S., Heath D.A., Ratcliffe J.G. Development and validation of an immunoradiometric assay of parathyrin-related protein in unextracted plasma. Clin. Chem. 1991, 37:678-685.
46. Reinhardt T.A., Horst R.L., Orf J.W., Hollis B.W. A microassay for 1,25-dihydroxyvitamin D not requiring high performance liquid chromotography: application to clinical studies. J. Clin. Endocrinol. Metab. 1984, 58:91-98.
47. Seiden-Long I., Vieth R. Evaluation of a 1,25-dihydroxyvitamin D enzyme immunoassay. Clin. Chem. 2007, 53:1104-1108.
48. Stokes F.J., Ivanov P., Bailey L.M., Fraser W.D. The effects of sampling procedures and storage conditions on short-term stability of blood-based biochemical markers of bone metabolism. Clin. Chem. 2011, 57:138-140.
49. 2 in human serum using isotope-dilution liquid chromatography-tandem mass spectrometry. Anal. Chem. 2010, 82:1942-1948.
50. Yuan C., Kosewick J., He X., Kozak M., Wang S. Sensitive measurement of serum 1alpha,25-dihydroxyvitamin D by liquid chromatography/tandem mass spectrometry after removing interference with immunoaffinity extraction. Rapid Commun. Mass Spectrom. 2011, 25:1241-1249.